A marked increase in the age-standardized mesothelioma incidence and mortality rates began in the 1960s after the massive use of asbestos during World War II and thereafter
2019
Key concepts
- gene-environment interaction
- mortality rate
- next-generation sequencing
- western europe
- clinical trials
- overall survival
- extrapleural pneumonectomy
- carcinogenic
- chromothripsis
- immunotherapy
- pathogenic
- united states
- Li-Fraumeni syndrome
- Food and Drug Administration
- mesothelioma
- The Cancer Genome Atlas
- cytoreductive surgery
- asbestos
- incidence rate
- whole-exome sequencing
- Positron emission tomography
- histone deacetylase
- computed tomography
- magnetic resonance imaging
- phosphatidylinositol 3-kinase
- Simian virus 40
- cancer syndromes
- preventive measure
- australia
- endobronchial ultrasound
Scholarcy highlights
- A marked increase in the age-standardized mesothelioma incidence and mortality rates began in the 1960s after the massive use of asbestos during World War II and thereafter
- As the cohorts of asbestos workers vanish because of old age, increasing percentages of mesotheliomas, especially peritoneal mesotheliomas, occur in individuals who are not occupationally exposed to asbestos
- These mesotheliomas may be caused by environmental exposure, genetic predisposition, or GxE interaction
- Pathogenic germline mutations of BRCA1-asssociated protein 1 and, less frequently, of other tumor suppressor genes have been detected in approximately 12% of patients
- This subgroup of genetically linked mesotheliomas occurs in younger individuals who rarely report asbestos exposure, with a M:F ratio of 1:1 and survival from 5 to 10 or more years
- Eighteen studies in 12 countries comprising 665 cases were included; a significantly increased risk of pleural mesothelioma was reported for both household exposure and neighborhood exposure
- Genetic testing of relatives helps detect those who inherited the mutations and who will benefit from early detection screening, which can be life-saving
- As we wait for the outcome of the ongoing clinical trials that, we hope, will improve therapeutic options, there are things that can be done to help patients: 1) reduce the percentage of misdiagnosis, estimated at 14%
Need more features? Save interactive summary cards to your Scholarcy Library.